eriparatide (750 mcg), a bioactive parathyroid hormone fragment, is used in bone metabolism research. It stimulates osteoblast activity, promotes bone formation, enhances bone density, and supports studies on osteoporosis treatment and fracture healing mechanisms in experimental models.
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, and must not be misused in any way that contravenes MHRA regulations or applicable laws.
Secured and trusted checkout with
1
Free Delivery
Free delivery on all orders above £100
2
Secure Payments
Selection of secure payments
3
Support 24/7
Contact us 24 hours a day, 7 days a week
Please complete your information below to login.
Sign In
Registered Customers
Create New Account
Forgot Password
Teriparatide is a synthetic form of parathyroid hormone (PTH) used as an anabolic (bone-building) agent to treat severe osteoporosis. Unlike common anti-resorptive medications that only slow bone loss, teriparatide actively stimulates new bone formation, improving bone density and quality.
Key benefits of teriparatide include:
Significant Increase in Bone Density: It increases bone mineral density (BMD) at the spine (9–13%) and hip (2.5–5%).
Drastic Reduction in Fractures: It reduces the risk of new vertebral fractures by up to 65% and non-vertebral fragility fractures by over 50% in high-risk patients.
Superiority in Severe Cases: It is highly effective for patients with severe osteoporosis, including those with previous vertebral fractures or those who have failed other treatments.
Improved Bone Quality: It improves trabecular (inner) and cortical (outer) bone microarchitecture, reversing structural deterioration.
Treatment of Steroid-Induced Osteoporosis: It is effective in treating osteoporosis caused by long-term corticosteroid use.
Accelerated Fracture Healing: Off-label uses show potential in enhancing bone healing for fractures that are slow to unite (non-union).
Periodontal Regeneration: It has been shown to improve alveolar bone repair in the jaw.
Key Considerations:
Administration: It is a daily, self-administered subcutaneous injection.
Duration: Therapy is typically limited to a maximum of 2 years.
Follow-up: It should be followed by an antiresorptive agent (like bisphosphonates) to maintain the gains in bone density.
Side Effects: Common, usually mild side effects include nausea, headache, dizziness, and injection site reactions.
Teriparatide acts "anabolically," stimulating osteoblast activity to form new bone, making it a powerful tool for rebuilding skeletal structure in cases of high fracture risk.
Please complete your information below to login.
Sign In
Create New Account